Deal Watch: AbbVie Exits Inherited CRISPR-Cas9 Team-Up With Editas
Executive Summary
Editas regains rights to ocular programs first partnered with Allergan in 2017. Newly public F-star will focus on bispecific antibodies for cancer, TriSalus acquires oncology candidate from Dynavax.
You may also be interested in...
TriSalus Thinks Its Drug/Device Strategy Can Optimize IO Regimens
The firm licensed the TLR9 agonist SD-101 from Dynavax to test with its pressure-enabled drug delivery technology in liver and pancreatic settings where immuno-oncology has shown moderate efficacy or less.
Biogen Builds Out Parkinson's Pipeline With Denali Deal
Biogen will pay Denali $560m up front plus a $465m equity investment in exchange for co-development and co-commercialization rights to clinical-stage LRRK2 inhibitors for Parkinson's disease.
Evotec Links Up With Secarna On Cutting-Edge Antisense Technology
Evotec has gained access to next-generation antisense technology through forging a strategic partnership with the small German biotech, Secarna, and they aim to make available a joint antisense pipeline of new therapeutic options for industry partners.
Need a specific report? 1000+ reports available
Buy Reports